These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 8724015)

  • 1. HMG-CoA reductase inhibitors and bile lithogenicity: cholesterol supersaturation or nucleation defect?
    Ahmed HA; Jazrawi RP; Northfield TC
    Eur J Gastroenterol Hepatol; 1996 Mar; 8(3):195-6. PubMed ID: 8724015
    [No Abstract]   [Full Text] [Related]  

  • 2. Does the HMG-CoA reductase inhibitor pravastatin influence nucleation of cholesterol crystals in supersaturated model bile?
    Smit JW; Van Erpecum KJ; Gadella MM; Van de Heyning BJ; Van Berge-Henegouwen GP
    Eur J Gastroenterol Hepatol; 1996 Mar; 8(3):197-200. PubMed ID: 8724016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of CS-514, a competitive inhibitor of hydroxymethylglutaryl coenzyme A reductase, on cholesterol gallstone formation in hamsters.
    Koide K; Hayashi K; Horiuchi I; Kajiyama G
    Biochim Biophys Acta; 1989 Sep; 1005(1):65-71. PubMed ID: 2505850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitory effects of pravastatin, a competitive inhibitor of hydroxymethylglutaryl coenzyme A reductase, on cholesterol gallstone formation in prairie dogs.
    Tazuma S; Hatsushika S; Aihara N; Sagawa H; Yamashita G; Sasaki M; Sasaki H; Mizuno S; Tao S; Kajiyama G
    Digestion; 1992; 51(3):179-84. PubMed ID: 1521718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of withdrawal of pravastatin on biliary lipid composition in humans.
    Muraca M; Baggio G; Vilei MT; Martini S; Cianci V; Crepaldi G
    Atherosclerosis; 1996 Jun; 123(1-2):133-7. PubMed ID: 8782844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simvastatin, a competitive inhibitor of HMG-CoA reductase, lowers cholesterol saturation index of gallbladder bile.
    Duane WC; Hunninghake DB; Freeman ML; Pooler PA; Schlasner LA; Gebhard RL
    Hepatology; 1988; 8(5):1147-50. PubMed ID: 3047037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation: epidemiological study in an unselected population.
    Caroli-Bosc FX; Le Gall P; Pugliese P; Delabre B; Caroli-Bosc C; Demarquay JF; Delmont JP; Rampal P; Montet JC;
    Dig Dis Sci; 2001 Mar; 46(3):540-4. PubMed ID: 11318529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nucleation time and fatty acid composition of lecithin in human gallbladder bile.
    Hatsushika S; Tazuma S; Kajiyama G
    Scand J Gastroenterol; 1993 Feb; 28(2):131-6. PubMed ID: 8441906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of long-term treatment with low-dose pravastatin on biliary lipid and bile acid composition in patients with nonfamilial hyperlipoproteinemia.
    Tazuma S; Takizawa I; Kunita T; Mizuno T; Watanabe T; Teramen K; Horikawa K; Ochi H; Yamashita Y; Aihara N
    Metabolism; 1995 Nov; 44(11):1410-2. PubMed ID: 7476326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced cholesterol absorption in hamsters by crilvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
    Hajri T; Chanussot F; Férézou J; Riottot M; Lafont H; Laruelle C; Lutton C
    Eur J Pharmacol; 1997 Feb; 320(1):65-71. PubMed ID: 9049604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol.
    Reihnér E; Rudling M; Ståhlberg D; Berglund L; Ewerth S; Björkhem I; Einarsson K; Angelin B
    N Engl J Med; 1990 Jul; 323(4):224-8. PubMed ID: 2114543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of the 3-hydroxy, 3-methylglutaryl coenzyme A reductase inhibitor pravastatin on bile composition and nucleation of cholesterol crystals in cholesterol gallstone disease.
    Smit JW; van Erpecum KJ; Renooij W; Stolk MF; Edgar P; Doornewaard H; Vanberge-Henegouwen GP
    Hepatology; 1995 Jun; 21(6):1523-9. PubMed ID: 7768495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biliary proteins. Unique inhibitors of cholesterol crystal nucleation in human gallbladder bile.
    Holzbach RT; Kibe A; Thiel E; Howell JH; Marsh M; Hermann RE
    J Clin Invest; 1984 Jan; 73(1):35-45. PubMed ID: 6690482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
    Hsu I; Spinler SA; Johnson NE
    Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increase in serum and bile cholesterol and HMG-CoA reductase by lovastatin in rats.
    Yamauchi S; Linscheer WG; Beach DH
    Am J Physiol; 1991 Apr; 260(4 Pt 1):G625-30. PubMed ID: 2018137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of pravastatin on biliary lipid composition and bile acid synthesis in familial hypercholesterolaemia.
    Hoogerbrugge-vd Linden N; de Rooy FW; Jansen H; van Blankenstein M
    Gut; 1990 Mar; 31(3):348-50. PubMed ID: 2108908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bile acid derived HMG-CoA reductase inhibitors.
    Kramer W; Wess G; Enhsen A; Bock K; Falk E; Hoffmann A; Neckermann G; Gantz D; Schulz S; Nickau L
    Biochim Biophys Acta; 1994 Nov; 1227(3):137-54. PubMed ID: 7986821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lovastatin alters biliary lipid composition and dissolves gallstones: a long-term study in prairie dogs.
    Abedin MZ; Narins SC; Park EH; Smith PR; Kirkwood KS
    Dig Dis Sci; 2002 Oct; 47(10):2192-210. PubMed ID: 12395892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does bilirubin play a role in the pathogenesis of both cholesterol and pigment gallstone formation? Direct and indirect influences of bilirubin on bile lithogenicity.
    Nakai K; Tazuma S; Ochi H; Chayama K
    Biochim Biophys Acta; 2001 Dec; 1534(2-3):78-84. PubMed ID: 11786294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.